The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Tec-Dara in patients with R/R myeloma: analysis of MajesTEC-3 based on cytogenetic & functional risk
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses an analysis of the MajesTEC-3 study (NCT05083169), which evaluated the efficacy of teclistamab plus daratumumab (Tec-Dara) in patients with relapsed/refractory (R/R) multiple myeloma (MM) based on cytogenetic and functional risk. Dr Banerjee highlights that Tec-Dara dramatically outperformed standard therapies in patients with high-risk cytogenetic abnormalities and functional high-risk disease biology, with significant improvements in progression-free survival (PFS) and measurable residual disease (MRD)-negative complete response (CR). He notes that Tec-Dara may be a “great equalizer” in relapsed myeloma, potentially closing the gap for patients who have been left behind by previous advances. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
